A New Three-Hit Mouse Model of Neurodevelopmental Disorder with Cognitive Impairments and Persistent Sociability Deficits.
Imane Mouffok, Caroline Lahogue, Thomas Cailly, Thomas Freret, Valentine Bouet, Michel Boulouard
Brain Sciences December 20, 2024 DOI: 10.3390/brainsci14121281 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal model study (three-hit mouse model) Peer reviewed |
|---|---|
| Population | Female mice |
| Intervention | phencyclidine |
| Dose | 10 mg/kg/day |
| Duration | Phencyclidine from 8 to 10 weeks of age; behavioral testing 1 and 6 weeks after the end of treatment |
| Keywords | Behavior Glutamate Maternal separation Phencyclidine Psychosis Serine racemase Social impairment Stress |
| Key points | Three-hit mice (serine racemase deletion, maternal separation, and phencyclidine) showed persistent hyperlocomotion and social behavior impairment, while spatial working memory deficits were not persistent. The authors contend the model has strong construct and face validity for negative-like symptoms of schizophrenia and supports glutamate dysfunction in behavioral symptoms. |
Abstract
Cognitive deficits and negative symptoms associated with schizophrenia are poorly managed by current antipsychotics. In order to develop effective treatments, refining animal models of neurodevelopmental disorders is essential. To address their multifactorial etiology, we developed a new three-hit mouse model based on the hypoglutamatergic hypothesis of the pathology combined with early stress, offering strong construct validity. Thus, a genetic susceptibility (serine racemase deletion) was associated with an early environmental stress (24 h maternal separation at 9 days of age) and a further pharmacological treatment with phencyclidine (PCP, a glutamate receptor antagonist treatment, 10 mg/kg/day, from 8 to 10 weeks of age). The face validity of this model was assessed in female mice 1 and 6 weeks after the end of PCP treatment by a set of behavioral experiments investigating positive- and negative-like symptoms and cognitive deficits. Our results showed that the three-hit mice displayed persistent hyperlocomotion (positive-like symptoms) and social behavior impairment deficits (negative-like symptoms) but non-persistent spatial working memory deficits (cognitive symptoms). Our work confirms the usefulness of a three-hit combination to model, particularly for negative-like symptoms associated with schizophrenia and other psychiatric disorders. The model therefore gathers powerful construct and face validities and supports an involvement of glutamate dysfunction in behavioral symptoms.
Citations in the library
Cites 13
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Study of a New Schizophrenomimetic Drug—Sernyl Archives of Neurology And Psychiatry March 1, 1959
- Reviewing the ketamine model for schizophrenia Journal of Psychopharmacology November 20, 2013
- Understanding the role of the NMDA receptor subunit, GluN2D, in mediating NMDA receptor antagonist-induced behavioral disruptions in male and female mice. Journal of Neuroscience Research 2024
and 8 more in the library